Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 10/20 | 0.42 |
| ▸ | CA2 | P00918 | 10/20 | 0.42 |
| ▸ | CA9 | Q16790 | 10/20 | 0.42 |
| ▸ | CA1 | P00915 | 9/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 9/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.38 |
| ▸ | FEN1 | P39748 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25839306 | 0.85 | ALDH1A1 (0.43) | ALDH1A1CA12CA2CA9CA1 | |
| SCHEMBL5700438 | 0.79 | CA12 (0.46) | ALDH1A1CA12CA2CA9CA1 | |
| SCHEMBL25838445 | 0.78 | GSTO1 (0.44) | ALDH1A1CA12CA2CA9CA1 | |
| SCHEMBL394384 | 0.76 | CA12 (0.60) | CA12CA2CA9CA1CA14 | |
| SCHEMBL4808842 | 0.75 | CA12 (0.44) | ALDH1A1CA12CA2CA9CA1 | |
| SCHEMBL31173473 | 0.74 | CA12 (0.40) | ALDH1A1CA12CA2CA9CA1 | |
| SCHEMBL6618815 | 0.74 | CA12 (0.47) | ALDH1A1CA12CA2CA9CA1 | |
| SCHEMBL3783321 | 0.74 | CA12 (0.43) | CA12CA2CA9CA1CA14 | |
| SCHEMBL30908488 | 0.72 | GAA (0.58) | ALDH1A1CA12CA2CA9CA1 | |
| SCHEMBL1439407 | 0.72 | GAA (0.58) | ALDH1A1CA12CA2CA9CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4464699-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF | Lisen Therapeutics, Inc. (US) | 2024-11-20 | — | — | EP | disclosed |
| US-20240360145-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF | LISEN THERAPEUTICS, INC. | 2024-10-31 | — | — | US | disclosed |
| WO-2023134582-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF | 上海立森印迹医药技术有限公司 | 2023-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360145-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF | DPYD, TYMP, TYMS | ALDH1A1 406/4885CA12 3837/4885CA2 3361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.